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Background: Teduglutide, a recombinant analog of human glucagon-like peptide (GLP)-2, is a novel therapy recently
approved for the treatment of adult patients with short bowel syndrome who are dependent on parenteral support.
Previous studies assessing the effect of GLP-2 on gastric emptying in humans have yielded inconsistent results, with
some studies showing no effect and others documenting a GLP-2–dependent delay in gastric emptying. The primary
objective of this study was to assess the effect of teduglutide on gastric emptying of liquids in healthy subjects, as
measured by the pharmacokinetics of acetaminophen.
Methods: This double-blind, parallel-group, single-center study enrolled and randomized 36 healthy subjects (22 men,
14 women) to receive subcutaneous doses of teduglutide 4 mg or placebo (2:1 ratio; 23:13) once daily on Days 1
through 10 in the morning. Gastric emptying of a mixed nutrient liquid meal was assessed by measuring acetaminophen
levels predose and at 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 3.5, 4, 5, 6, 8, 10, 12, and 14 hours after administration of 1000 mg
acetaminophen on Days 0 and 10. The primary study endpoint was a pharmacokinetic analysis of acetaminophen
absorption in subjects receiving teduglutide or placebo.
Results: No significant differences in gastric emptying of liquids (acetaminophen area under the concentration [AUC] vs
time curve from time 0 to the last measurable concentration, AUC extrapolated to infinity, maximum concentration
[Cmax], and time to Cmax) were observed on Day 10 in subjects receiving teduglutide 4 mg versus subjects receiving
placebo. There were no serious adverse events (AEs), deaths, or discontinuations due to an AE reported during the study.
Conclusions: Teduglutide 4 mg/day for 10 days does not affect gastric emptying of liquids in healthy subjects as
measured by acetaminophen pharmacokinetics. No unexpected safety signals were observed.
Trial registration: This study was registered at ClinicalTrials.gov, identifier NCT01209351.
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The proglucagon gene yields a single mRNA transcript
expressed in the intestines, pancreas, and central ner-
vous system (CNS) [1-3]. Tissue-specific cleavage of the
resulting proglucagon precursor protein generates sev-
eral peptides with distinct biological activity [3]. In the
intestines, the proglucagon-derived proteins glucagon-* Correspondence: jolene.berg@davita.com
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reproduction in any medium, provided the orlike peptide (GLP)-1 and GLP-2 are expressed in the
enteroendocrine L cells and are secreted in response to
food intake [4-6]. The primary effects of GLP-1 are to
increase postprandial insulin levels, inhibit glucagon se-
cretion, and slow gastric emptying [7-15], whereas the
primary effects of GLP-2 are to increase growth of intes-
tinal epithelium, maintain intestinal mucosal morph-
ology and function, and regulate energy intake [16-19].
Unlike GLP-1, GLP-2 has limited effect on insulin secre-
tion or glucose homeostasis [20-22]. Furthermore, ind. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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glucagon secretion [21,23].
Multiple animal and human studies have demon-
strated a delay in gastric emptying with GLP-1 or gluca-
gon, another protein encoded by the proglucagon gene
[7-12,24,25]. Because GLP-1 and GLP-2 are both derived
from proglucagon and secreted following nutrient stimu-
lation, it has been hypothesized that they coregulate gas-
tric motility [26]. Indeed, in preclinical studies, GLP-2
significantly decreased the amplitude and frequency of
postprandial gastric contractions and promoted gastric
muscle relaxation [26,27]. However, conflicting results
have emerged from studies on human subjects, with
some reporting no effect of GLP-2 and others demon-
strating a GLP-2–dependent inhibition of gastric empty-
ing [21,28-30]. The divergent outcomes may have been
influenced by differences between the studies, including
variations in the amounts of GLP-2 delivered, the
methods used to evaluate gastric emptying, and the con-
tent of test meals administered [21,28-30].
Teduglutide, a recombinant GLP-2 analog, is a novel
therapy recently approved for the treatment of adult
patients with short bowel syndrome (SBS) who are
dependent on parenteral support [31,32]. SBS is defined
as a clinically significant reduction in intestinal absorp-
tive capacity resulting from surgical resection of the in-
testine due to disease, trauma, congenital defects, or
complications of surgery [33,34]. Teduglutide promotes
expansion of the remaining normal intestinal epithelium by
increasing villus height and crypt depth in the small bowel
mucosa, leading to increased absorptive area [31,32,35]. In
a phase III, placebo-controlled trial, teduglutide significantly
reduced parenteral nutrition and/or intravenous fluid (PN/
IV) volume requirements and the number of infusion days
required in patients with SBS [36].
Teduglutide is a synthetic protein that differs from na-
tive GLP-2 by the substitution of glycine for alanine at
the second position from the N-terminus [37]. This
single amino acid substitution renders it resistant toFigure 1 Study design. SC = subcutaneous.degradation by dipeptidyl peptidase-4 [37,38]. As a re-
sult, the half-life (t½) of teduglutide is increased com-
pared with native GLP-2 following subcutaneous
injection (t½ of 180–330 minutes vs 60–90 minutes, re-
spectively) [39,40]. Because GLP-2 reduces gastric motil-
ity and delays gastric emptying, at least in animal and
some human studies [26,27,29,30], it is possible that
teduglutide, a similar but distinct molecular entity, may
also inhibit gastric emptying. Modification of gastric
emptying rate may alter the bioavailability of concomi-
tantly administered drugs and modulate drug-drug
interactions [41]. Thus, given the recent approval of
teduglutide, clarification of the physiological effects of
this novel peptide would provide important information
to the medical community.
The primary objective of this study was to assess the
effect of teduglutide on gastric emptying of liquids in
healthy subjects as gauged by acetaminophen pharmaco-




In this double-blind, single-center, US-based, parallel-
group study, 36 healthy domiciled subjects were random-
ized in a 2:1 ratio to receive subcutaneous teduglutide
4 mg or placebo daily for 10 days (Figure 1).
Subjects were randomized according to a randomization
scheme generated by the sponsor or their designee. All
doses of study drug for each subject were taken from the
kit designated for that subject. Both subjects and investiga-
tors were blinded to the identity of the study drug admin-
istered; vials containing teduglutide and placebo were
identical in appearance.
The RCRC Independent Review Board, LLC, of Austin,
TX approved the study protocol and informed consent
procedure before study initiation. The study was con-
ducted in accordance with the Declaration of Helsinki,
applicable International Conference on Harmonisation
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registered at ClinicalTrials.gov, identifier NCT01209351.
Subjects
The study enrolled adults aged 18 to 45 years in good
health who provided informed consent for participation.
The study was conducted in healthy volunteers to elim-
inate the confounding effects of gastrointestinal (GI)
disease. Key exclusion criteria included history of GI ab-
normality that could affect GI motility (including small
bowel or colonic resection, inflammatory bowel disease,
irritable bowel disease, and colon or GI tract cancer),
allergy or sensitivity to acetaminophen, history of hepa-
titis or pancreatitis, evidence of liver inflammation, preg-
nancy or lactation, and body mass index >30 kg/m2.
Prohibited prior and concomitant medications were gen-
erally those that may have affected gastric emptying,
confounded efficacy or safety measurements, potentially
posed a safety concern, or adversely potentiated or an-
tagonized study drug treatment. Subjects were asked to
abstain from alcoholic beverages and/or other alcohol-
containing products from 48 hours before check-in until
the last scheduled evaluation and blood sample collec-
tion before discharge on Day 11. Caffeinated beverages
were not allowed during the gastric emptying assess-
ments on Days 0 and 10 because caffeine may affect gas-
tric emptying [43]. Hormonal contraceptives were also
prohibited based on the potential for interference with
acetaminophen metabolism [44].
Treatments
Teduglutide 4 mg or placebo was administered by daily
subcutaneous abdominal injection in a volume of 0.4 mL
in the morning on Days 1 through 10. On Day 10, study
drug was administered following an overnight fast and 3
hours before administration of a commercially available
liquid meal providing 240 kcal and containing 10 g pro-
tein, 4 g fat, and 41 g carbohydrate (Boost®, Nestlé Health-
care Nutrition, Florham Park, NJ). To ensure treatment
compliance, study medication was administered under the
direct supervision of the site investigator.
Acetaminophen extra-strength liquid 1000 mg (30 mL)
was administered on Days 0 and 10 immediately before a
standard Boost meal and 3 hours after teduglutide or pla-
cebo on Day 10.
Assessments
Pharmacodynamics of gastric emptying
The primary study endpoint was a PK analysis of acet-
aminophen absorption in subjects receiving teduglutide
or placebo. Blood levels of acetaminophen were mea-
sured at 0, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 3.5, 4, 5, 6, 8,
10, 12, and 14 hours after acetaminophen administration
on Days 0 and 10 (Table 1).Safety
Safety assessments included monitoring of adverse
events (AEs), clinical laboratory tests, electrocardiogram,
physical examination, and vital signs. For each AE re-
corded, an intensity level (ie, mild, moderate, or severe)
was assigned. Mild AEs generally did not interfere with
daily activities, required no special treatment, and were
usually transient. Moderate AEs impaired daily activities
but were usually easily resolved. Severe AEs interrupted
daily activities and required vigorous therapeutic inter-
vention. Serious AEs and AEs considered related to
study drug were recorded through 30 days after the last
study drug dose.
Statistical analysis
The sample size of 36 was based on phase I consider-
ations for hypothesis generation rather than power
considerations. The intent-to-treat (ITT) population in-
cluded all randomized subjects who received at least 1
dose of study medication and had at least 1 PK/pharma-
codynamic (PD) measurement. The PK/PD population in-
cluded all subjects from the respective population who had
at least 3 PK measurements. The safety population in-
cluded all randomized subjects who received at least 1 dose
of study drug and who had any follow-up information.
For acetaminophen absorption, PK parameters esti-
mated from plasma concentration (Days 0 and 10) in-
cluded area under the plasma concentration versus time
curve (AUC) from time 0 to the last measurable concen-
tration (AUC0–last) and extrapolated to infinity (AUC0–inf ),
maximum plasma concentration (Cmax), and time to Cmax
(tmax). PK parameters were estimated from the actual time
of sampling and were calculated using noncompartmental
analysis. Analysis of covariance (ANCOVA) using baseline
(Day 0) values and sex as covariates was used to analyze
the acetaminophen PK data and calculate differences in
gastric emptying of liquids between teduglutide and pla-
cebo for AUC and Cmax parameters. A rank-adjusted non-
parametric ANCOVA was used for tmax.
Safety data were summarized using descriptive statis-
tics for quantitative data and frequency counts for quali-
tative data. AEs were coded using Medical Dictionary
for Regulatory Activities terminology.
SAS/STAT® version 9.1 (SAS Institute, Cary, NC) was
used to analyze the data.
Results
Subject disposition
Between September and November 2010, 36 subjects
were randomized to receive teduglutide (n = 23) or pla-
cebo (n = 13). All subjects received at least 1 dose of
study medication and had at least 1 PK measurement
(ITT population). In the placebo group, 1 subject with-
drew consent for personal reasons and discontinued
Table 1 Day 10 gastric emptying and pharmacokinetic schedule
Example clock
time
7:00 7:15 7:30 8:00 9:00 10:00 10:15 10:30 10:45 11:00 11:15 11:30 12:00 13:00 13:30 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00 24:00
Gastric emptying
schedule, hours







Standard meal* X X*
Boost® meal X


















Table 2 Subject demographics
Demographic variable Placebo (n = 13) Teduglutide 4 mg (n = 23)
Mean (SD) age, y 32.5 (7.0) 31.4 (7.4)
Mean (SD) weight, kg 80.9 (12.4) 70.3 (12.0)
Mean (SD) height, cm 173.6 (10.7) 169.0 (8.7)
Mean (SD) body
mass index, kg/m2
26.7 (2.2) 24.5 (3.1)
Sex, n (%)
Male 8 (62) 14 (61)
Female 5 (38) 9 (39)
Race, n (%)
Black 4 (31) 5 (22)
White 9 (69) 18 (78)
Ethnicity, n (%)
Hispanic or Latino 8 (62) 17 (74)
Not Hispanic
or Latino
5 (38) 6 (26)
Figure 2 Plasma acetaminophen concentrations vs time. A, Day 0, befo
drug administration. LOQ = limit of quantification.
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was not included in the PK/PD population. Subjects
were well matched for demographics and baseline char-
acteristics between the 2 groups (Table 2).
Gastric emptying
Compared with placebo, teduglutide treatment for 10 days
had no appreciable effect on gastric emptying of liquids as
determined by acetaminophen PK parameters. Although
acetaminophen absorption appears to be somewhat higher
in the teduglutide group compared with the placebo group
on both Day 0 and Day 10, the absorption curves for the
teduglutide group and the placebo group on Day 10 were
not significantly different from the corresponding curves
on Day 0 (Figure 2A and B). The Day 10 absorption curves
also did not differ significantly between the treatment
groups. At Day 10, no significant differences were observed
between the 2 groups in AUC0–last, AUC0–inf, Cmax, or tmax
(Table 3). Within the teduglutide group, acetaminophen PK
parameters were similar at Day 0 and Day 10 (AUC0–last,
60,105 ± 13,028 vs 60,984 ± 15,710 ng∙hour/mL, respectively;re administration of study drug. B, Day 10, following 10 days of study
Table 3 Acetaminophen pharmacokinetic parameters on day 10 (PK/PD population*)
Pharmacokinetic parameter, mean ± SD Placebo (n = 12) Teduglutide 4 mg (n = 23) P value
AUC0–last, ng∙hour/mL 47,652 ± 9377 60,984 ± 15,710 0.32
AUC0–inf, ng∙hour/mL 50,036 ± 9706 65,279 ± 17,039 0.26
Cmax, ng/mL 10,679 ± 2246 12,677 ± 3821 0.28
tmax, hour 1.5 1.7 0.65
AUC = area under the curve; AUC0–last = AUC from time 0 to the last measurable concentration; AUC0–inf = AUC from time 0 extrapolated to infinity;
Cmax =maximum plasma concentration; PD = pharmacodynamic; PK = pharmacokinetic; tmax = time to Cmax.
*1 patient in the placebo group withdrew consent on Day 7 and therefore did not have PK/PD data for Day 10.
Table 4 Treatment-emergent adverse events reported
in ≥5 % of subjects in the teduglutide group
Variable, n (%) Placebo (n = 13) Teduglutide 4 mg (n = 23)
Treatment-emergent AEs 9 (69) 14 (61)
Abdominal distention 2 (15) 8 (35)
Constipation 2 (15) 5 (22)
Headache 2 (15) 5 (22)
Abdominal pain 1 (8) 5 (22)
Nausea 0 5 (22)
Dyspepsia 0 2 (9)
Eructation 0 2 (9)
Extremity pain 0 2 (9)
AE = adverse event.
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Cmax, 13,319 ± 3155 vs 12,677 ± 3821 ng/mL; tmax, 1.6 vs
1.7 hour). Similarly, the placebo group showed no apparent
differences in PK parameters at Day 0 versus Day 10
(AUC0–last, 47,551 ± 9483 vs 47,652 ± 9377 ng∙hour/mL,
respectively; AUC0–inf, 50,360 ± 10,001 vs 50,036 ±
9706 ng∙hour/mL; Cmax, 11,124 ± 2939 vs 10,679 ± 2246 ng/
mL; tmax, 1.5 vs 1.5 hour).
Safety
Treatment-emergent AEs for subjects who received at
least 1 dose of study drug with any follow-up informa-
tion are shown in Table 4. Overall, 23 (64%) subjects ex-
perienced a treatment-emergent AE. There were no
serious AEs, deaths, or discontinuations due to an AE
during the study. Mild and moderate AEs were reported
in 20 subjects (56%) and 3 subjects (8%), respectively; no
severe AEs were reported. Changes from baseline in
clinical laboratory parameters, electrocardiogram, phys-
ical examination, and vital signs were not clinically
significant.
Discussion
In this study, teduglutide administered at 4 mg/day for
10 days did not affect gastric emptying of liquids in
healthy subjects as measured by acetaminophen PK. Pre-
vious studies evaluating gastric emptying following ad-
ministration of GLP-2, a similar but distinct molecular
entity, have yielded conflicting results [21,28-30]. Com-
parisons with and among these studies are hampered by
heterogeneities in trial design, study populations, GLP-2
dosages, routes of GLP-2 administration, and timing of
treatments. Nonetheless, results with teduglutide pre-
sented here are in agreement with 2 prior studies dem-
onstrating no effect of infused native GLP-2 (0.75–2.25
pmol ∙ kg–1 ∙ min–1 for 180–390 minutes) on gastric
emptying rate following a 250−to 310-kcal solid meal,
as determined by either scintigraphic measurement or
13C-sodium octanoate breath test [21,28]. In contrast,
2 other studies have reported delayed gastric emptying
with GLP-2 [29,30]. In one of these studies, conducted in
healthy adults following a 7.5-kcal liquid meal, antral
emptying time was increased by 9.5 minutes following
GLP-2 (initial bolus of 4.5 pmol/kg followed by infusion at1.0 pmol ∙ kg–1 ∙ min–1 for 60 minutes) compared with
placebo (P = 0.049), as determined by ultrasound scanning.
GLP-2 infused at a lower rate (0.5 pmol ∙ kg–1 ∙ min–1)
after the initial bolus did not significantly affect antral
emptying time [29]. Contrary to the modest results
reported by Nagell et al., Jeppesen et al. described a
30-minute increase in time to 50% gastric emptying of
solids following 35 days of treatment with subcutaneous
GLP-2 (400 μg twice daily; P = 0.002) using a scintigraphic
technique [30]. In this case, however, the study enrolled
patients with SBS who may have had baseline disturbances
in gastric emptying. For example, half of the patients in
the Jeppesen study had an end-jejunostomy, which in a
previous study was correlated with accelerated emptying
of gastric liquids for patients with SBS [45]. Furthermore,
end-jejunostomy patients have diminished intestinal secre-
tion of GLP-2 [30,46]. For these reasons, GLP-2 may
have a greater effect on gastric emptying in the end-
jejunostomy population.
The liquid meal provided to study subjects contained
fats in addition to carbohydrates and proteins. Previous
studies suggest that the lipid phase empties more slowly
than the aqueous phase in the context of a mixed solid-
liquid meal [47,48]. However, when fats are homoge-
nized with liquids before ingestion, as is the case with a
liquid-only meal, both fats and the aqueous phase empty
at the same rate [49]. Therefore, it is likely that the data
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both fats and the aqueous phase of the liquid meal.
Recently, rapid tachyphylaxis has been documented for
GLP-1–dependent inhibition of gastric emptying in humans
following prolonged infusion [50], prompting the question
of whether the physiological effects of GLP-2 or teduglutide
could also be affected by tachyphylaxis. Presently, however,
no data are available concerning the potential for tachyphyl-
axis with GLP-2 or teduglutide with regard to gastric empty-
ing. Of the 4 published studies evaluating the effects of
GLP-2 on gastric emptying in humans, none provided mul-
tiple measurements of gastric emptying following GLP-2 ad-
ministration [21,28-30]. The results presented in this study
show no effect of teduglutide on gastric emptying following
10 days of subcutaneous administration; however, the study
was not designed to evaluate gastric emptying rates earlier
in the treatment period, or following multiple meals con-
sumed within a period of less than 24 hours. However, sev-
eral studies have demonstrated sustained biological activity
of GLP-2 or teduglutide over extended treatment periods.
For example, mice who received subcutaneous GLP-2 for 12
weeks showed a progressive increase in small bowel weight
over the course of the study [17]. Patients with SBS treated
with subcutaneous teduglutide (0.05 mg/kg/day) experi-
enced continued reductions in PN/IV volume requirements
throughout a 52-week study. Furthermore, 11 of 19 patients
in the same study who were nonresponders following 24
weeks of teduglutide achieved a clinically significant re-
sponse, defined as a ≥20% reduction in PN/IV volume from
baseline, by Week 52 [51]. These data indirectly suggest
continued improvement with long-term teduglutide treat-
ment, with no dampening of response.
Teduglutide was well tolerated in this study. No unex-
pected safety signals were observed. AEs were generally
mild, with no severe AEs reported. The most common AEs
observed in this study were gastrointestinal related, which is
consistent with the known mechanism of action of teduglu-
tide. These results are also in agreement with clinical trials
for teduglutide conducted in patients with SBS dependent
on parenteral support. In two 6-month, placebo-controlled,
phase III studies, gastrointestinal-related AEs were the most
frequently reported class of AEs among patients receiving
0.05 mg/kg/day teduglutide [31,36].
This study was limited by the small sample size and use
of healthy volunteers. Furthermore, the methods applied
in this study assess gastric emptying of liquids only. How-
ever, the appearance of ingested acetaminophen in the
plasma is an established and validated measure of gastric
emptying kinetics [42] and has been used extensively in
the analysis of GLP-1 receptor agonists [52-57].
Conclusions
The results presented here suggest that teduglutide does
not act to delay liquid-phase gastric emptying in healthysubjects. Therefore, teduglutide is unlikely to modulate
the bioavailability of orally administered concomitant
medications through inhibition of gastric motility in this
population. However, the effects of teduglutide on gastric
emptying in patients with SBS remain to be investigated.
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